Fan Yao-Yun, Neubert Hendrik
Pharmacokinetics Dynamics & Metabolism, Pfizer, Inc., 1 Burtt Road, Andover, Massachusetts 01810, United States.
Anal Chem. 2016 Apr 19;88(8):4239-47. doi: 10.1021/acs.analchem.5b03900. Epub 2016 Apr 4.
Neonatal Fc receptor (FcRn) is the homeostatic receptor responsible for the long half-life of endogenous IgG by protecting it from lysosomal degradation. Understanding systemic FcRn tissue expression is important to predict and design the half-life of therapeutic antibodies and Fc-coupled biotherapeutics. To this end, we measured human FcRn (hFcRn) tissue expression in Tg32, a human FcRn knock-in transgenic mouse model, for which a strong correlation of drug clearance to humans has been demonstrated. Building an hFcRn tissue expression profile in Tg32 was enabled by the development of a tissue preparation procedure composed of bead-based protein extraction and protein precipitation using acetone followed by pellet digestion with trypsin. Digests were then loaded onto an online peptide immuno-affinity flow configuration hyphenated with reversed phase nanoflow chromatography and coupled with high resolution mass spectrometry to quantify hFcRn derived peptides. The workflow allowed bypassing some of the challenges typically associated with membrane protein analysis. We demonstrated acceptable precision and bias for measuring hFcRn in tissue matrices, typically within 20% coefficient of variation and relative error. We also report hFcRn expression in several Tg32 tissues. We anticipate that establishing a quantitative approach for hFcRn in tissues will enable the systematic measurement of hFcRn concentrations to further increase the accuracy of physiologically based pharmacokinetic (PBPK) models for PK prediction of Fc-containing biotherapeutics. This is anticipated to improve the translation of pharmacokinetic data from preclinical model systems to humans.
新生儿Fc受体(FcRn)是一种稳态受体,通过保护内源性IgG免受体溶酶体降解,从而使其具有较长的半衰期。了解FcRn在全身组织中的表达对于预测和设计治疗性抗体及Fc偶联生物治疗药物的半衰期非常重要。为此,我们在Tg32(一种人FcRn基因敲入转基因小鼠模型)中测量了人FcRn(hFcRn)的组织表达,该模型已被证明与人类药物清除率具有很强的相关性。通过开发一种组织制备程序,即在基于磁珠的蛋白质提取和使用丙酮进行蛋白质沉淀后,用胰蛋白酶消化沉淀,从而构建了Tg32中的hFcRn组织表达谱。然后将消化产物加载到与反相纳流色谱联用的在线肽免疫亲和流配置上,并与高分辨率质谱联用,以定量hFcRn衍生肽。该工作流程绕过了一些通常与膜蛋白分析相关的挑战。我们证明了在组织基质中测量hFcRn具有可接受的精密度和偏差,变异系数和相对误差通常在20%以内。我们还报告了hFcRn在几种Tg32组织中的表达。我们预计,建立一种针对组织中hFcRn的定量方法将能够系统地测量hFcRn浓度,从而进一步提高基于生理学的药代动力学(PBPK)模型预测含Fc生物治疗药物药代动力学的准确性。这有望改善药代动力学数据从临床前模型系统到人类的转化。